VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.
Yao X., Tan J., Lim KJ., Koh J., Ooi WF., Li Z., Huang D., Xing M., Chan YS., Qu JZ., Tay ST., Wijaya G., Lam YN., Hong JH., Lee-Lim AP., Guan P., Ng MSW., He CZ., Lin JS., Nandi T., Qamra A., Xu C., Myint SS., Davies JOJ., Goh JY., Loh G., Tan BC., Rozen SG., Yu Q., Tan IBH., Cheng CWS., Li S., Chang KTE., Tan PH., Silver DL., Lezhava A., Steger G., Hughes JR., Teh BT., Tan P.
Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncodingcis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identifiedZNF395as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor eliminationin vitroandin vivoVHLloss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α-HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 without overtly affecting preexisting promoter-enhancer interactions. Subtype-specific driver mutations such asVHLmay thus propagate unique pathogenic dependencies in ccRCC by modulating epigenomic landscapes and cancer gene expression.Significance:Comprehensive epigenomic profiling of ccRCC establishes a compendium of somatically alteredcis-regulatory elements, uncovering new potential targets including ZNF395, a ccRCC master regulator. Loss ofVHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2α and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter-enhancer complexes.Cancer Discov; 7(11); 1284-305. ©2017 AACR.See related commentary by Ricketts and Linehan, p. 1221This article is highlighted in the In This Issue feature, p. 1201.